US Material Events SEC 8-K Filings — June 10, 2026

10-06-2026

VolitionRX Ltd (VNRX) priced a $4.6 million public offering on June 7, 2026, issuing 2,960,000 shares and warrants for up to 1,480,000 shares at a combined price of $1.55 per share. The offering includes participation from new and existing investors, with potential additional gross proceeds of up to $2.3 million from warrant exercises, though no assurance of exercise is given. The offering is expected to close on June 9, 2026.

• · The offering is being conducted under an effective shelf registration statement on Form S-3 (File No. 333-283088), filed with the SEC on November 8, 2024, and declared effective on April 18, 2025.
• · Each warrant has an exercise price of $1.55 per share, is exercisable immediately upon issuance, and expires five years after issuance.
• · Maxim Group LLC is the sole placement agent, and the offering is expected to close on June 9, 2026.
• · The company cautions that no assurance can be given that any warrants will be exercised.
• · VolitionRX is a multinational epigenetics company focused on developing blood tests for cancer and NETosis-related diseases like sepsis.

10-06-2026

CervoMed Inc. announced a private placement financing with expected gross proceeds of approximately $10.5 million, extending cash runway into Q2 2027. The company plans to focus on strategic partnering to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB). However, the Phase 3 trial initiation is contingent on securing a partnership and/or additional financing, and the company faces risks from potential dilution and reliance on future funding.

• · The private placement includes 3,360,377 Units, each consisting of common stock or pre-funded warrant, Series B warrant, and Series C warrant.
• · Series B warrants expire June 11, 2031; Series C warrants expire June 11, 2027; pre-funded warrants have no expiration.
• · The company has alignment with FDA (Nov 2025), UK MHRA, and EMA (Jan 2026) on potential registration path for neflamapimod in DLB.
• · Phase 3 dosing regimen is 50mg TID of stable crystal form; initial Phase 3 clinical drug batch manufactured and released.
• · A 39-week chronic toxicity study increased neflamapimod's no adverse effect level threefold and widened safety margin to ~30-fold above clinically active exposures.
• · Phase 2a trial in nfvPPA fully enrolled; interim biomarker data expected early Q4 2026, 24-week clinical data in Q1 2027.
• · EXPERTS-ALS Phase 2a trial expected to dose first patient in Q4 2026.
• · Insiders including Joshua S. Boger, John J. Alam, and Sylvie Grégoire participated in the financing.

10-06-2026

J&J Snack Foods Corp. entered into Amendment No. 2 to its Second Amended and Restated Credit Agreement, extending the maturity date to June 5, 2031, and adding a $200 million incremental commitment. The amendment also removes certain merged entities as borrowers, updates interest rate margins and financial covenants, and increases various subsidiary debt and investment thresholds. The changes provide the company with additional financial flexibility and a longer-term credit facility.

• · The amendment removes Federal Pretzel Baking Company, Swirl Holdings, Icee of Hawaii, NY Pretzel, DD Acquisition Holdings, and Dippin' Dots Holding as borrowers due to mergers.
• · Interest rate margins are tiered based on Consolidated Net Leverage Ratio, ranging from 0.95% to 2.00% for SOFR loans and 0.00% to 1.00% for ABR loans.
• · Unused fees range from 0.10% to 0.30% based on leverage ratio.
• · The definition of Material Subsidiary now includes any wholly-owned subsidiary that owns Intellectual Property or is needed to reach 90% of consolidated net revenues or total assets.
• · A new 'Specified Event of Default' definition covers defaults under Sections 8.1(a), (b), (h), or (i).
• · Financial reporting deadlines remain 45 days after each fiscal quarter end for unaudited statements.
• · The amendment increases various subsidiary debt and investment caps from prior levels (specific prior caps not disclosed).

10-06-2026

American Airlines Group Inc. held its 2026 Annual Meeting on June 10, 2026, where stockholders approved the amended and restated 2023 Incentive Award Plan (increasing shares reserved by 16.5 million), ratified KPMG as independent auditor, and elected all 12 director nominees. However, stockholders did not approve a proposal to limit officer liability, nor two stockholder proposals on written consent and cumulative voting.

• · Stockholders did NOT approve the proposal to amend the Restated Certificate of Incorporation to limit officer liability — 270,464,196 For, 22,139,185 Against, 968,316 Abstain; failed to achieve majority of shares outstanding.
• · Stockholder proposal for right to act by written consent failed: 59,402,069 For vs. 232,549,168 Against.
• · Stockholder proposal for cumulative voting failed: 10,018,677 For vs. 281,843,732 Against.
• · All 12 director nominees were elected; Martin H. Nesbitt received the highest number of Against votes (32,817,804) among nominees.
• · Ratification of KPMG as auditor passed overwhelmingly: 438,670,632 For, 9,494,939 Against.
• · Advisory vote on executive compensation (Say-on-Pay) passed with 284,141,512 For, 8,637,705 Against.
• · Broker non-votes totaled 155,803,612 shares on all non-routine proposals.

10-06-2026

EquipmentShare.com Inc (EQPT) announced the appointment of Damian Giangiacomo and Harley Miller to its Board of Directors, effective June 8, 2026, following the completion of its IPO. Concurrently, board members Henry Yeagley and John Weinstein stepped down as part of an orderly board transition. The changes reflect the company's evolution as a public company, with Giangiacomo bringing corporate governance and finance expertise and Miller contributing deep historical knowledge of the company.

• · Damian Giangiacomo will serve on the Audit Committee of the Board.
• · Henry Yeagley joined the Board in May 2022; John Weinstein joined in December 2024.
• · Harley Miller previously served on EquipmentShare's Board from December 2016 during its private growth phase.
• · Damian Giangiacomo co-founded Nexus Capital Management LP in 2013, which has approximately $5 billion in assets under management.
• · Harley Miller founded Left Lane Capital in 2019 and previously spent nine years as a Principal at Insight Venture Management, LLP.
• · John Weinstein stated that Insight Partners remains a dedicated shareholder.

10-06-2026

Factorial Inc. reported a reduced net loss of $8.6M for Q1 2026, a 33.4% improvement from the $12.9M loss in Q1 2025, with operating expenses declining to $6.5M from $13.1M. However, cash and cash equivalents decreased 11.9% sequentially to $25.4M, and the company's accumulated deficit widened to $264.2M. The de-SPAC transaction closed on June 5, 2026, providing gross proceeds of approximately $112.1M.

• · Research and development net expense improved to $(1.9M) in Q1 2026 from $(6.8M) in Q1 2025.
• · Selling, general and administrative expenses decreased to $4.5M from $6.4M YoY.
• · Total liabilities increased to $41.4M as of March 31, 2026 from $34.5M at year-end 2025.
• · Cash used in operating activities was $6.1M in Q1 2026, roughly flat versus $6.1M in Q1 2025.
• · Stock-based compensation was $1.5M in Q1 2026, down from $3.9M in Q1 2025.
• · The company had no revenue in either period.
• · Substantial doubt about going concern was raised prior to the de-SPAC proceeds.
• · Foreign currency translation loss was $(298,000) in Q1 2026, compared to a gain of $8,000 in the prior year.

10-06-2026

Aditxt, Inc. (NASDAQ: ADTX) announced a definitive business combination agreement valuing its 100%-owned subsidiary Ignite Proteomics at an implied equity value of approximately $150 million. Upon closing, Ignite is expected to separate from Aditxt and become an independent NYSE-listed public company through a newly formed holding company (Pubco), while Aditxt continues as a separate Nasdaq-listed company. The transaction is subject to customary closing conditions, including shareholder approvals and SEC registration, and is intended to unlock value for Aditxt while providing Ignite with dedicated capital and visibility to advance its functional proteomics platform in precision oncology.

• · Ignite's current commercial focus is in breast cancer, with a broader development strategy intended to support expansion into additional tumor types and treatment settings.
• · Net proceeds from the transaction are expected to support Ignite's commercialization initiatives, clinical evidence generation, working capital needs and general corporate purposes.
• · Following closing, the combined company is expected to be led by Ignite's management team.
• · The acquisition corp. is a special purpose acquisition company (SPAC) whose identity is not disclosed in the press release.
• · Aditxt acquired Ignite as part of its strategy to identify, acquire and advance differentiated health innovation platforms.

10-06-2026

Purebase Corporation announced the appointment of Dr. Amy T. Clemens as Chief Financial Officer, effective June 5, 2026. Dr. Clemens previously served as interim CFO for two years during the company's inception and returns from the defense industry. The filing does not disclose any financial metrics or performance data, so no period-over-period comparisons or quantitative trends are available.

• · Dr. Clemens previously served as interim CFO for 2 years during Purebase's inception before returning to the defense industry.
• · The appointment is effective June 5, 2026.
• · The company describes itself as a 'highly diversified mineral resource company' and a 'diversified resource company' that acquires, develops and markets high-value minerals and agricultural products.

10-06-2026

Keel Infrastructure Corp. (NASDAQ/TSX: KEEL), the successor to Bitfarms Ltd., closed a $458 million offering of 1.250% convertible senior notes due 2032, generating approximately $445.4 million in net proceeds. A portion of the proceeds funded capped call transactions to offset dilution up to a share price of $11.86, while the remainder will support general corporate purposes including data center development. However, the company has a limited operating history with losses, faces risks from its strategic pivot from Bitcoin mining to HPC infrastructure, and the notes carry a low 1.250% coupon, indicating potential credit risk.

• · The convertible notes mature on January 15, 2032, unless earlier repurchased, redeemed, or converted.
• · Interest is payable semi-annually on January 15 and July 15, beginning January 15, 2027.
• · The initial conversion price is approximately $7.41 per share, a 25% premium over the June 4, 2026 closing price of $5.93.
• · The capped call cap price is $11.86 per share, a 100% premium over the same closing price.
• · Keel may settle conversions in cash, common stock, or a combination, at its election.
• · The notes were offered only to qualified institutional buyers under Rule 144A and exempt from Canadian prospectus requirements.
• · Keel relies on TSX Section 602.1 exemption for eligible interlisted issuers.
• · On April 1, 2026, Keel became the ultimate parent of Bitfarms via a statutory plan of arrangement, effectively redomiciling Bitfarms from Canada to the U.S.
• · The company has a 2.2 GW pipeline of digital infrastructure with grid interconnections in Pennsylvania, Washington, and Québec.
• · Forward-looking statements highlight risks including limited operating history, losses, strategic pivot to HPC, reliance on third-party suppliers, Bitcoin price volatility, and potential dilution from note conversion.

10-06-2026

Einride AB, a global leader in autonomous and electric freight, completed its business combination with Legato Merger Corp. III, approved by Legato shareholders on June 4, 2026. The transaction valued Einride at a pre-money equity value of approximately $1.35 billion and included an oversubscribed $113 million PIPE financing supported by new and existing investors. Einride's American depositary shares and warrants will begin trading on Nasdaq under the symbols "ENRD" and "ENRDW" on June 10, 2026.

• · Einride was founded in 2016.
• · The business combination was approved by Legato shareholders at an extraordinary general meeting on June 4, 2026.
• · The PIPE was supported by new and existing investors, including Stockholm-based EQT Ventures and a global asset management company based on the West Coast of the United States.
• · TD Cowen served as lead financial and capital markets advisor to Einride and lead placement agent on the PIPE.
• · BTIG, LLC served as capital markets advisor to Legato and as co-placement agent on the PIPE.
• · Legal counsel for Einride was provided by DLA Piper LLP (US), Advokatfirma DLA Piper Sweden KB, and Conyers Dill & Pearman LLP.
• · Legal counsel for Legato included Graubard Miller, Lindskog Malmström Advokatbyrå AB, and Appleby (Cayman) Ltd.
• · Greenberg Traurig, LLP served as legal counsel to the placement agents.
• · Einride serves customers across North America, Europe, and the Middle East.

10-06-2026

Aldeyra Therapeutics appointed Darlene Deptula-Hicks to its board of directors on June 9, 2026. Ms. Deptula-Hicks brings over 30 years of experience in public and private life sciences, including senior executive and CFO roles, and will support the company's progress toward potential commercialization of therapies for immune-mediated diseases. The filing does not disclose any financial results or performance metrics, so no period-over-period comparisons are available.

• · Ms. Deptula-Hicks currently serves as acting CFO of Normunity Inc., a clinical-stage cancer biotech.
• · She previously served as CFO of F-star Therapeutics, Inc.
• · Aldeyra's product candidates include RASP modulators ADX-248, ADX-246, and reproxalap (for dry eye disease and allergic conjunctivitis), and ADX-2191 (intravitreal methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa).

10-06-2026

Pantages Capital Acquisition Corp (PGACU) filed an 8-K on June 10, 2026, announcing proposed amendments to its Third Amended and Restated Memorandum and Articles of Association to extend the deadline to complete a business combination. The proposal allows up to 12 monthly extensions from June 6, 2026, to June 6, 2027, providing a total of up to 30 months post-IPO. If no business combination is completed by the final deadline, the company will redeem public shares and dissolve.

• · The extension period runs from June 6, 2026 to June 6, 2027.
• · The company may extend up to 12 times, each by one month, for a total of up to 12 additional months.
• · If no business combination is completed by June 6, 2027, the company must cease operations, redeem public shares, and liquidate and dissolve.
• · Up to $100,000 of trust interest may be used for dissolution expenses before redemption proceeds are distributed to public shareholders.
• · Redemption price equals the aggregate amount in the trust account (including interest not previously released, less taxes and dissolution expenses) divided by the number of public shares outstanding.

10-06-2026

Metagenomi Therapeutics, Inc. (MGX) announced the resignation of board member Brian C. Thomas, Ph.D., effective June 9, 2026, with no disagreement cited. At the same time, the company held its 2026 annual meeting, where stockholders elected Juergen Eckhardt and Eric Bjerkholt as Class II directors and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026. The meeting had a quorum of 19,116,207 shares (50.8% of outstanding shares), but the director elections saw significant broker non-votes (10,382,607) and relatively low 'for' votes, indicating potential shareholder disengagement.

• · The director election had 10,382,607 broker non-votes for both nominees, representing 54.3% of the quorum shares.
• · Eric Bjerkholt received 8,251,289 'for' votes (94.5% of votes cast excluding broker non-votes), while Juergen Eckhardt received 7,296,718 'for' votes (83.5% of votes cast excluding broker non-votes).
• · Ratification of PricewaterhouseCoopers LLP passed overwhelmingly with 18,483,295 'for' votes (99.7% of votes cast).
• · The record date for the annual meeting was April 13, 2026, and the proxy statement was filed on April 27, 2026.

10-06-2026

Reborn Coffee, Inc. announced the appointment of Jung Jae Lim as Chief Executive Officer, effective immediately, following the departure of Jay Kim as Co-Chief Executive Officer on June 4, 2026. The Board expressed confidence in Mr. Lim's leadership and stated the transition will not impact operations, expansion plans, franchise development, or financial reporting. No financial figures or performance metrics were disclosed in the filing.

• · Jung Jae Lim had served as Co-Chief Executive Officer and Director since March 2026 before assuming full CEO role.
• · The Board affirmed no impact on day-to-day operations, domestic/international expansion, franchise development, or financial reporting obligations.
• · The filing includes forward-looking statements cautioning about risks including the Company's ability to continue as a going concern due to recurring net losses.

10-06-2026

Hut 8 Corp. subsidiary Beacon Point DC LLC completed a $4.25 billion private offering of 6.129% Senior Secured Notes due 2042 to finance the development of a 352 MW data center in Nueces County, Texas, which will be leased to a high-investment-grade tenant (rated AA- or higher). The notes bear interest at 6.129% per annum, mature on November 30, 2042, and include amortization beginning May 30, 2030. The offering provides substantial capital for the project, but the high interest rate and long-term debt create significant fixed obligations, and the project's success depends on timely construction and tenant performance.

• · The Notes were issued at 100% of principal amount and will amortize semi-annually beginning May 30, 2030.
• · Interest on the Notes is payable semi-annually on May 30 and November 30, starting November 30, 2026.
• · The Issuer may redeem the Notes at make-whole price before May 30, 2042, and at 100% of principal after that date.
• · Upon a Data Center Lease Termination Event, the Issuer may redeem all or part of the Notes at 100% of principal plus accrued interest.
• · If the Debt Service Coverage Ratio falls below 1.1:1.0 after the Initial Commencement Date, the Issuer may redeem a portion of the Notes to restore the ratio to approximately 1.1:1.0.
• · The Indenture includes covenants limiting additional indebtedness, dividends, investments, liens, asset sales, and affiliate transactions.
• · Upon a change of control, the Issuer must offer to repurchase the Notes at 101% of principal plus accrued interest.
• · Upon certain asset sales or a Data Center Lease Termination Default, the Issuer must offer to repurchase the Notes at 100% of principal plus accrued interest.
• · The tenant is described as a high-investment-grade company rated AA- or higher.

10-06-2026

Trane Technologies announced the appointment of Donny Simmons as Chief Operating Officer, effective July 1, 2026, reporting to Chair and CEO Dave Regnery. The move aligns leadership structure with the company's increased scale and expanding market opportunities, as Trane has nearly doubled annual revenue since 2020. No negative or flat performance metrics were disclosed in this filing.

• · Simmons previously served as Group President of the Americas region, overseeing commercial and residential HVAC, transport refrigeration, and life science solutions.
• · Simmons joined the company in 2001 and has led Commercial HVAC North America, EMEA, and several global industrial businesses.
• · Simmons has experience across general management, sales, manufacturing, and finance.

10-06-2026

Industrial Logistics Properties Trust (ILPT) held its 2026 annual meeting on June 9, 2026, where all seven trustee nominees were elected, and shareholders voted in favor of an annual non-binding advisory vote on executive compensation. The Board also expanded from seven to eight members and elected Elena B. Poptodorova as an Independent Trustee, effective immediately. While all director nominees received majority support, Lisa Harris Jones and Adam Portnoy each received over 8.3 million withhold votes (approximately 29% of votes cast), indicating notable shareholder dissent.

• · The Board increased its size from seven to eight members to accommodate the new trustee.
• · Elena B. Poptodorova was appointed to the Audit, Compensation, and Nominating and Governance Committees.
• · Ms. Poptodorova has served as a trustee of Office Properties Income Trust since 2017 and previously served as a director of TravelCenters of America Inc. until its acquisition by BP in May 2023.
• · She was the Bulgarian ambassador to the United States from 2002-2008 and 2010-2016.
• · The company entered into an indemnification agreement with Ms. Poptodorova on substantially the same terms as with other trustees and executive officers.
• · Broker non-votes totaled 21,001,576 on all director elections and advisory proposals (except auditor ratification).
• · The auditor ratification received 49,402,172 For votes with only 255,510 Against and 47,959 Abstain, and no broker non-votes.
• · The Board determined to hold an annual non-binding advisory vote on executive compensation, consistent with the shareholder vote.

10-06-2026

Wheels Up Experience Inc. held its 2026 Annual Meeting on June 9, 2026, with 92.6% of outstanding shares represented. Stockholders approved all four proposals, including the election of four Class II directors, advisory approval of executive compensation, ratification of Grant Thornton LLP as auditor, and an amendment to the 2021 Long-Term Incentive Plan to increase available shares from 3,007,484 to 6,757,484 (post-reverse split) and extend the plan termination date to March 31, 2036. The filing reflects routine governance actions with strong shareholder support, though broker non-votes were significant on certain proposals.

• · The 1-for-20 reverse stock split became effective after market close on April 24, 2026.
• · The LTIP Amendment was previously approved by the Board and Compensation Committee on March 31, 2026.
• · Broker non-votes totaled 39,845,045 shares on director elections, executive compensation, and the LTIP Amendment.
• · Ratification of Grant Thornton LLP received 544,018,799 votes for, 3,043,148 against, and 587,022 abstentions (no broker non-votes).
• · The LTIP termination date was extended to March 31, 2036.

10-06-2026

On June 9, 2026, Northern States Power Company (Wisconsin) entered into a Bond Purchase Agreement to issue $250 million in aggregate principal amount of 5.48% First Mortgage Bonds due June 15, 2041. The offering was placed solely by Huntington Securities, Inc., and net proceeds of approximately $249 million will be used for general corporate purposes. No other financial metrics or comparisons are provided in this filing.

• · The bonds are secured by a first mortgage lien on substantially all of NSP-Wisconsin’s real and fixed properties (subject to limited exceptions).
• · The bonds may be redeemed at NSP-Wisconsin’s option at any time before December 15, 2040 at a make-whole redemption price (greater of 100% of principal or make-whole amount plus accrued interest); on or after December 15, 2040, at 100% of principal plus accrued interest.
• · Events of default include non-payment of principal/premium, 30-day default on interest, 60-day default on sinking fund payments, bankruptcy, and 60-day uncured covenant breaches.
• · The bonds were offered in reliance on Section 4(a)(2) of the Securities Act (private placement) and are not registered under the Securities Act or state securities laws.

10-06-2026

LB Pharmaceuticals Inc announced that Chief Medical Officer Dr. Anna Eramo will resign effective June 15, 2026, for personal reasons, and transition to an advisor role through September 15, 2026. The company stated the departure is unrelated to clinical program operations and does not expect a material impact on clinical development activities or milestones. A search for a replacement is underway, and the company has experienced clinical teams to oversee ongoing trials.

• · Dr. Eramo will receive her current base salary on a monthly basis until June 15, 2027, if she remains engaged as a consultant through September 15, 2026.
• · She will receive 100% of her target annual bonus for 2026 on a prorated basis.
• · The company will reimburse COBRA healthcare premium costs for up to 12 months following the Separation Date.
• · The Separation Agreement includes confidentiality and non-disparagement covenants and a release of claims.

10-06-2026

Astrana Health, Inc. held its 2026 Annual Meeting on June 10, 2026, where stockholders approved the Amended and Restated 2024 Equity Incentive Plan, increasing the reserved shares by 1,000,000 and extending the plan term to March 24, 2036. All nine director nominees were elected, Ernst & Young LLP was ratified as independent auditor, and the advisory vote on executive compensation passed. However, director J. Lorraine Estradas received the highest number of withheld votes (3,244,703) among nominees, indicating some shareholder dissent.

• · The record date for the annual meeting was April 14, 2026.
• · Broker non-votes totaled 8,356,118 on all director elections and on Proposals 3 and 4.
• · Proposal 2 (ratification of auditor) had no broker non-votes and passed with 43,722,509 votes for, 19,566 against, and 30,520 abstentions.
• · The advisory vote on executive compensation (Proposal 3) received 34,119,199 for, 1,209,072 against, and 88,206 abstentions.
• · The 2024 Plan approval (Proposal 4) received 34,679,879 for, 701,303 against, and 35,295 abstentions.
• · Director J. Lorraine Estradas had the highest withheld votes (3,244,703) among all nominees.
• · Director John Chiang received the most votes for (34,104,046) among nominees.

10-06-2026

Eikon Therapeutics appointed Ma. Fatima D. Francisco as a Class I director effective June 15, 2026, with an annual retainer of $50,000 and an option to purchase 85,937 shares at $8.96 per share. No other material changes were disclosed.

• · Ms. Francisco will serve on the Compensation Committee.
• · Option vests in 48 equal monthly installments subject to continued service.
• · Ms. Francisco entered into standard indemnification agreement.
• · No arrangements or understandings with other persons regarding her selection.
• · No related person transactions required to be disclosed.

10-06-2026

Apple Hospitality REIT, Inc. announced that Elizabeth S. Perkins, Senior Vice President and Chief Financial Officer, has been appointed as the Company's principal accounting officer effective June 10, 2026, succeeding Rachel Labrecque, who passed away on June 9, 2026.

• · Ms. Perkins assumed the additional role of principal accounting officer on June 10, 2026.
• · Ms. Labrecque's passing occurred on June 9, 2026.
• · Ms. Perkins' biographical information is incorporated by reference from the Company's definitive proxy statement filed on April 2, 2026.

10-06-2026

Syndax Pharmaceuticals held its 2026 Annual Meeting on June 10, 2026, where stockholders approved the 2026 Equity Incentive Plan (reserving 7,200,000 shares) and the 2026 Employee Stock Purchase Plan, both effective immediately. The 2026 Plan replaces the expired 2015 Omnibus Incentive Plan, and the 2026 ESPP does not carry over shares from the 2015 ESPP. All director nominees were elected, and all five proposals passed, though the 2026 Plan received a relatively narrow approval margin (33.3M for vs. 25.4M against).

• · The 2026 Plan includes share recycling provisions from the 2015 Plan's outstanding awards.
• · The 2026 ESPP has two components: a Section 423 qualified component for U.S. employees and a non-qualified component for foreign employees.
• · Shares available under the 2015 ESPP will not roll over to the 2026 ESPP.
• · The 2026 Plan received a relatively narrow approval with 33,333,263 votes for and 25,392,051 against (excluding broker non-votes).
• · All other proposals passed with strong majorities: advisory say-on-pay (55.7M for), auditor ratification (66.6M for), and 2026 ESPP (58.7M for).

10-06-2026

Vir Biotechnology, Inc. announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the Board size from seven to eight members. Mr. Coughlin will serve as a Class III director and Chair of the Audit Committee, effective immediately. He will receive standard non-employee director compensation, including stock option and restricted stock unit grants under the 2019 Equity Incentive Plan.

• · Mr. Coughlin was not selected pursuant to any arrangement or understanding, and no related party transactions exist under Item 404(a) of Regulation S-K.
• · The appointment is effective immediately, with Mr. Coughlin's term running until the 2028 annual meeting of stockholders.
• · Standard form indemnity agreement entered into with Mr. Coughlin, referenced from the Company's 2019 Form S-1 filing.
• · No prior period data or comparisons are provided; this is a single-event filing.

10-06-2026

Sensei Biotherapeutics, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, increasing its authorized capital stock from 210,000,000 shares to 310,000,000 shares, consisting of 300,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock. The amendment was approved by the Board and stockholders, and became effective upon filing with the Delaware Secretary of State on June 10, 2026. This corporate action provides the company with additional authorized shares for potential future financing, acquisitions, or other strategic purposes.

• · The Certificate of Incorporation was originally filed on December 1, 2017 under the name PPI Holdings, Inc.
• · Previous amendments were filed on December 29, 2020, February 8, 2021, and June 12, 2025.
• · The par value for both Common Stock and Preferred Stock remains $0.0001 per share.
• · The amendment was adopted in accordance with Section 242 of the DGCL.

10-06-2026

Dell Technologies Inc. entered into a $6.0 billion credit agreement on June 10, 2026, with JPMorgan Chase Bank as administrative agent and a syndicate of lenders including Bank of America, Barclays, Citibank, Goldman Sachs, Wells Fargo, and HSBC. The facility includes a $500 million letter of credit sublimit and is structured with pricing tied to Dell's credit ratings, ranging from 0.825% to 1.450% for Term SOFR loans and 0.065% to 0.240% for the unused line fee. The agreement also contains a consolidated interest coverage ratio covenant and other standard terms, but no period-over-period comparisons are available as this is a new facility.

• · The credit agreement is dated June 10, 2026, and includes Dell International L.L.C. and EMC Corporation as borrowers.
• · The facility has a pricing grid based on debt ratings from S&P, Moody's, and Fitch, with five pricing levels ranging from Level 1 (≥ BBB+/Baa1/BBB+) to Level 5 (≤ BB/Ba2/BB).
• · The Term SOFR Applicable Rate ranges from 0.825% (Level 1) to 1.450% (Level 5); the Base Rate ranges from 0.000% (Levels 1-2) to 0.450% (Level 5); the Unused Line Fee ranges from 0.065% (Level 1) to 0.240% (Level 5).
• · The agreement includes a consolidated interest coverage ratio covenant (Article VII, Section 7.03) and standard events of default (Article VIII).
• · The facility is arranged by JPMorgan Chase, Bank of America, Barclays, Citibank, Goldman Sachs, Wells Fargo, and HSBC as joint lead arrangers and joint bookrunners.

10-06-2026

Visium Technologies, Inc. terminated its Amended and Restated Letter of Intent to acquire ConnexUS AI Inc., after the Board determined the ConnexUS incubation had failed. The mutual release extinguishes all payment obligations, confirms ConnexUS retains full ownership of the ATHENA platform IP, and includes the resignation of Cheddi Rai from all officer and director positions at Visium. The Board now consists of Paul R. Taylor (Chairman & CEO), Mark Lucky (CFO), and David Pierce (Independent Director).

• · The LOI termination is effective as of June 9, 2026.
• · Visium has returned or destroyed all copies of ATHENA IP in its possession.
• · ConnexUS waived all payment obligations including Committed Contract Value, Minimum Monthly Fees, Pass-Through Costs, interest, liquidated damages, and collection costs.
• · The mutual release covers claims for breach of contract, breach of fiduciary duty, fraud, misrepresentation, unjust enrichment, quantum meruit, tortious interference, and securities law claims.
• · The agreement includes confidentiality and non-disparagement obligations.
• · Disputes will be resolved by binding arbitration in Broward County, Florida under the Revised Florida Arbitration Code.

10-06-2026

Sleep Number Corporation elected Colin M. Adams as a director on June 4, 2026, effective immediately. The Board now comprises 7 members, 6 of whom are independent under Nasdaq standards. Mr. Adams will receive a monthly fee of $40,000 for his service, with potential additional fees for extra activities.

• · No arrangement or understanding existed between Mr. Adams and any other person regarding his selection as a director.
• · No transactions requiring disclosure under Item 404(a) of Regulation S-K were reported.

10-06-2026

Broadridge Financial Solutions appointed Todd Diganci to its Board of Directors effective August 1, 2026, expanding the board to 10 members, eight of whom are independent. Diganci, former EVP, CFO, and CAO of FINRA, will serve on the Audit Committee. The appointment brings regulatory and financial expertise to support Broadridge's innovation and growth.

• · Broadridge processes over 7 billion communications annually and underpins daily average trading of over $15 trillion in tokenized and traditional securities globally.
• · Broadridge is part of the S&P 500 Index and employs over 15,000 associates in 21 countries.

10-06-2026

Perpetua Resources Corp. filed an 8-K on June 10, 2026, disclosing the adoption of the 2026 Equity Incentive Plan and related award agreements (RSU, PSU, DSU) effective June 2026. The filing also covers director/officer changes under Items 5.02 and 5.07, though specific departures or elections are not detailed in the provided content. No financial figures or period-over-period comparisons are included.

• · The 8-K includes Items 5.02 (Director/Officer Departure/Election), 5.07 (Submission of Matters to a Vote of Security Holders), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits).
• · Exhibits filed include the 2026 Equity Incentive Plan and forms of RSU, PSU, and DSU Award Agreements.
• · The report is signed by Mark Murchison, Chief Financial Officer, dated June 10, 2026.

10-06-2026

Fervo Energy (Nasdaq: FRVO) announced the promotion of Sarah Jewett to Chief Operating Officer (COO), effective June 10, 2026. Jewett, who joined the company in 2020 and previously led the strategy department, will oversee centralized corporate operations as the company accelerates its standardized geothermal development model. The filing highlights the company's growing project pipeline across utility offtake, AI hyperscaler demand, and industrial power applications, but provides no financial metrics or period-over-period comparisons.

• · Sarah Jewett spent her twenties running hydraulic fracturing crews for Schlumberger across the Permian, North Slope, and Western U.S. basins.
• · She holds an M.B.A. from Harvard Business School and a Bachelor of Engineering in Mechanical Engineering from Dartmouth College.
• · Jewett joined Fervo in 2020 to lead the strategy department after working at Select Energy Services.
• · The COO role is newly created to centralize supply chain, land, permitting, policy, and people functions as the company scales.

10-06-2026

Credit Acceptance Corporation announced the appointment of Joe Billante as Chief Financial Officer, effective July 27, 2026, succeeding Jay Martin, who will retire after 23 years with the company. Billante brings over 25 years of finance leadership experience from Barracuda Networks, eBay, and General Electric. As part of a planned transition, Martin will participate in Q2 earnings and remain engaged through August 31, 2026.

• · Billante served as CFO of Barracuda Networks, leading global finance through strategic transformation.
• · At eBay, Billante spent 13 years in senior roles including CFO for European and Greater China businesses and VP of Investor Relations.
• · Billante began his career at General Electric, including as CFO of a global division of GE Healthcare.
• · Jay Martin joined Credit Acceptance in 2003 and will remain actively engaged through August 31, 2026.
• · Martin will participate in the Q2 earnings call alongside management as part of the transition.

10-06-2026

WhiteHawk Income Corp (WHIC) entered into a Contribution Agreement on June 9, 2026, under which WhiteHawk Minerals LLC will contribute 100% of the membership interests of WhiteHawk Management LLC to WhiteHawk OP in exchange for Common Units equal to 75% of the Internalization Price divided by the IPO Price, plus a corresponding number of WHIC Class B Common Shares at $0.0001 per share. Additional earnout consideration of up to 25% of the same quotient may be issued based on WhiteHawk OP's EBITDA performance over three earnout years (July 2026 – June 2029), with thresholds ranging from $80.2M to $129M. The transaction is contingent upon the closing of WHIC's IPO and the execution of related documents.

• · The Contributor owns 100% of the membership interests of WhiteHawk Management LLC.
• · WhiteHawk Energy Services LLC, a wholly owned subsidiary of the Company, employs all employees providing services to WhiteHawk OP and its affiliates.
• · The Contribution Agreement includes a release of claims (Section 9.12) and restrictive covenants (Section 6.09).
• · The earnout is calculated based on 'Earnout EBITDA' as defined in the agreement, with specific thresholds for each of the three earnout years.
• · The A&R OP LPA, Management Employment Agreements, A&R WHIC Charter, and Registration Rights Agreement are exhibits to the agreement.
• · The transaction is subject to conditions precedent including the closing of the IPO and execution of the A&R OP LPA.

10-06-2026

Figure Technology Solutions, Inc. (Buyer) has entered into a definitive merger agreement to acquire Kiavi, Inc. (Company) through a merger of its wholly owned subsidiary, Project Mason Merger Sub, Inc., with and into Kiavi. The transaction is structured as a cash merger, with Kiavi stockholders receiving cash consideration per share, plus contingent rights to certain post-closing payments. The merger is subject to stockholder approval, regulatory approvals, and other customary closing conditions, and is expected to close following satisfaction of those conditions.

• · The merger agreement was executed on June 10, 2026.
• · Kiavi's board of directors has approved the merger and recommended stockholder approval.
• · Concurrently, Bridge Opportunities Loan Trust JV (organized by Buyer and the Securityholder Representative) is entering into an Equity Purchase Agreement with Kiavi to purchase certain assets and liabilities.
• · Key executives Arvind Mohan, Charles Goodwin, and Jonathan Muller are entering into Restrictive Covenants Agreements in favor of Buyer.
• · The merger is subject to the Requisite Stockholder Consent, which will be sought promptly after execution.
• · The surviving corporation will be a wholly owned subsidiary of Buyer.
• · Post-closing, the directors and officers of Merger Sub will become the directors and officers of the surviving corporation.
• · The consideration includes cash per share plus contingent rights to potential post-closing payments (expense fund release, adjustment surplus, escrow release).
• · Non-Converting Preferred Stock will receive its liquidation preference, with potential adjustments if post-closing payments exceed that preference.
• · The agreement includes provisions for dissenting shares, sanctioned shares, and treatment of company options, RSUs, and warrants.

10-06-2026

HNI Corporation entered into Amendment No. 3 to its Credit Agreement on June 10, 2026, to refinance all outstanding Initial Tranche B Term Loans (Existing Term Loans) with new 2026 Refinancing Term Loans totaling $498,750,000. The amendment involves Wells Fargo Bank as Administrative Agent, with Wells Fargo Securities, JPMorgan Chase, and U.S. Bank as joint lead arrangers. The refinancing is structured to convert or prepay existing loans and includes customary conditions, representations, and reaffirmations of credit obligations.

• · The amendment refinances all outstanding Initial Tranche B Term Loans (Existing Term Loans) under the original Credit Agreement dated September 5, 2025.
• · Lenders could choose between a Cashless Settlement Option (converting Existing Term Loans into 2026 Refinancing Term Loans of like principal) or a Post-Closing Settlement Option (prepayment and separate purchase of 2026 Repricing Term Loans).
• · Conditions precedent include receipt of legal opinions from multiple law firms, a solvency certificate, and a Borrowing Request for the new loans.
• · The amendment reaffirms all covenants, representations, and warranties of the Credit Agreement and does not constitute a novation.
• · The Certificate of Existence for The Hon Company LLC must be delivered within five business days after the effective date.

10-06-2026

Swarmer, Inc. entered into a Common Stock Purchase Agreement and Registration Rights Agreement with Lucid Capital Markets, LLC on June 10, 2026, allowing the company to sell up to 3,000,000 shares of common stock at its discretion over a 24-month period, at a per-share price equal to 98% of the VWAP during the applicable purchase period. The company also filed an initial registration statement on the same date and engaged Seaport Global Securities LLC as a qualified independent underwriter, agreeing to reimburse up to $55,000 for its services. This facility provides Swarmer with flexible financing for operations, expansion, and acquisitions, but it creates potential dilution for existing shareholders and does not guarantee any capital raise.

• · The purchase price per share for regular purchases is 98% of the VWAP during the applicable Purchase Date.
• · The default Minimum Price Threshold is 75% of the prior day's closing price if not specified otherwise.
• · Lucid's ownership is capped at 4.99% of outstanding shares.
• · The Purchase Agreement automatically terminates on the earliest of: 24 months from Commencement, when 3,000,000 shares have been purchased, if common stock is delisted, upon bankruptcy events, or upon appointment of a custodian.
• · The company may also execute Intraday Purchases after 10:00 a.m. and before 3:30 p.m. New York City time on trading days.
• · The company has the right to terminate the agreement at any time after Commencement with 10 trading days' notice without cost or penalty.
• · Lucid can terminate the agreement in specific circumstances, including uncured material breach, failed registration deadlines, or sustained trading suspension.
• · Seaport Global Securities will be reimbursed up to $55,000 for its QIU services and will receive no other compensation.

10-06-2026

Dream Finders Homes, Inc. completed its reincorporation from Delaware to Texas, effective June 9, 2026, converting from a Delaware corporation to a Texas corporation under the same name. The company's authorized capital stock remains 355,000,000 shares, consisting of 350,000,000 shares of Common Stock (289,000,000 Class A and 61,000,000 Class B) and 5,000,000 shares of Preferred Stock (including 150,000 Series A Convertible Preferred). The reincorporation does not change the company's principal business address in Jacksonville, Florida, or its operational structure.

• · The reincorporation was effective at 5:00 p.m. Eastern Time on June 9, 2026.
• · The registered office in Texas is at 1999 Bryan St., Suite 900, Dallas, Texas 75201, with CT Corporation System as registered agent.
• · Class B Common Stock carries 3 votes per share (based on conversion into Class A), while Class A Common Stock carries 1 vote per share.
• · Class B Common Stock is convertible at any time into Class A Common Stock on a 1:1 basis.
• · The certificate of formation allows shareholders holding a majority of voting power to approve fundamental business transactions without a separate class vote, unless preferred stock rights specify otherwise.
• · In a change of control transaction, Class A and Class B holders must be treated equally unless a majority of the affected class votes for different treatment.

10-06-2026

Tandy Leather Factory Inc. (TLF) disclosed in an 8-K filing that its Board approved increases to non-employee director cash retainers to $20,000, with additional fees for committee chairs and members, and accelerated vesting of all unvested RSUs effective June 9, 2026. The Board also appointed John Gehre as Chairman. At the annual meeting, all six director nominees were elected with strong support (over 4.3 million votes for each), and the ratification of Whitley Penn as auditor passed with 5,622,340 votes for versus 627,286 against. The advisory vote on executive compensation received 4,370,852 votes for and 455,754 against, indicating shareholder approval but with notable dissent.

• · All six director nominees received over 4.3 million votes for, with withheld votes ranging from 431,346 to 433,434.
• · Broker non-votes totaled 1,420,087 for each director election and for the advisory vote on executive compensation.
• · Ratification of Whitley Penn as auditor had 5,622,340 votes for, 627,286 against, and 1,000 abstentions.
• · Advisory vote on executive compensation: 4,370,852 for, 455,754 against, 3,933 abstentions.
• · The Board accelerated vesting of all unvested RSUs as of June 9, 2026; future RSUs will vest at grant date.

10-06-2026

American Eagle Outfitters Inc. entered into Amendment No. 2 to its Second Amended and Restated Credit Agreement, effective June 4, 2026, with unanimous lender consent. The amendment extends the maturity date to the fifth anniversary of the amendment's effective date (approximately June 2029) and makes other modifications to the existing credit facility. No financial terms or new borrowing amounts were disclosed in the filing.

• · The amendment was unanimously approved by 100% of the lenders immediately prior to the effective date.
• · The maturity date is extended to the fifth anniversary of the Amendment No. 2 Effective Date (June 4, 2026), i.e., approximately June 4, 2029.
• · The amendment includes reaffirmation of existing liens and security interests by both U.S. and Canadian loan parties.
• · Post-closing requirements include delivery of flood hazard determinations and related documentation within 90 days of the effective date.
• · The amendment is governed by New York law.

10-06-2026

Sadot Group Inc. filed a Current Report on Form 8-K on June 10, 2026, covering Items 1.01 (Entry into a Material Definitive Agreement), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), and 9.01 (Financial Statements and Exhibits). The filing indicates a material agreement entry and potential corporate governance changes, but no specific financial figures or performance metrics were disclosed in the filing header.

• · The filing includes Items 1.01, 5.03, and 9.01, suggesting a material agreement and possible amendments to governing documents.
• · The company's CIK is 0001701756, formerly known as Muscle Maker, Inc. until July 2023.
• · The filing date is June 10, 2026, and the document size is 8 MB.

10-06-2026

Netcapital Inc. (NCPLW) entered into a Securities Purchase Agreement with LABRYS FUND II, L.P. on June 3, 2026, under the exemption from securities registration pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b). The proceeds from the sale are designated for business development and general working capital. The agreement includes restrictive covenants limiting the Company from changing its business nature or engaging in material asset transactions until the note is paid or fully converted.

• · The agreement was entered under the exemption from securities registration under Section 4(a)(2) of the 1933 Act and Rule 506(b).
• · The Company covenants to use proceeds solely for business development and general working capital, with explicit prohibitions on repaying certain debts, making loans to affiliates, or violating applicable law.
• · The Company is restricted from changing the nature of its business or materially altering its asset structure until the note is paid in full or fully converted.
• · The Company represents solvency and continuing as a going concern, with no information suggesting inability to pay debts as they mature.
• · Extensive representations cover environmental compliance, property title, insurance adequacy, internal accounting controls, and compliance with the Foreign Corrupt Practices Act.
• · The Company certifies no disqualification events under Rule 506(d) of the 1933 Act and that it is not required to be registered as an investment company.

10-06-2026

Tango Therapeutics, Inc. entered into an underwriting agreement on June 9, 2026, to sell 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase up to 1,833,395 shares at $29.999 per warrant, with an option for underwriters to purchase an additional 3,000,009 shares. The expected net proceeds of approximately $566.5 million will be used for general corporate purposes, including R&D, pivotal trial expenses, and potential commercialization preparation, and are expected to fund operations into 2030. This offering provides significant capital runway but also dilutes existing shareholders.

• · The offering is expected to close on June 11, 2026, subject to customary closing conditions.
• · The shares and pre-funded warrants are sold under a Registration Statement on Form S-3ASR (File No. 333-291684).
• · The underwriting agreement includes customary representations, warranties, indemnification obligations, and termination provisions.
• · The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately, and do not expire.
• · Under the pre-funded warrants, a holder cannot exercise if it would result in beneficial ownership exceeding 4.99% or 9.99% (as elected) of outstanding common stock, with a 61-day notice requirement for changes up to 19.99%.
• · Use of proceeds includes research and development expenses, pivotal trial expenses, and potential commercialization preparations.
• · No prior period financial comparisons or performance metrics are reported.

10-06-2026

On June 8, 2026, DeFi Development Corp. announced the resignation of Parker White as Chief Operating Officer and Chief Investment Officer. The company entered into a separation agreement providing $250,000 in cash payments over twelve months and accelerated vesting of 213,272 unvested stock options, while also engaging Mr. White for consulting services at $8,333 per month.

• · The Separation Agreement includes a release of claims against the company.
• · Mr. White's consulting services will focus on transition of operations of certain validators owned by the company.
• · The effective date of resignation and separation is June 8, 2026.
• · The filing is dated June 10, 2026.

10-06-2026

RadNet, Inc. secured a $250 million incremental term loan to fund strategic growth, including acquisitions and organic expansion, while reducing the interest rate on its credit facility by 0.25%. The company's cash balance as of March 31, 2026, was $455 million, and the new loan adds to this liquidity. However, quarterly principal payments on the term loan increased from approximately $2.4 million to $3.1 million, reflecting higher debt service costs.

• · The incremental term loan matures on April 18, 2031, coinciding with the existing term loan maturity.
• · Call protection provided to term loan lenders for six months following the Third Amendment.
• · RadNet operates imaging centers in 11 states: Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas, and Virginia.
• · The interest rate on the term loan is now Term SOFR plus 2.00% or alternate base rate plus 1.00%.

10-06-2026

Braemar Hotels & Resorts Inc. entered into an agreement to sell three luxury hotel properties—The Ritz-Carlton Sarasota, Hotel Yountville, and Bardessono Hotel and Spa—for a total of $437.5 million in cash. The transaction is expected to close in 20-35 days, subject to customary conditions, but there is no guarantee of completion. No comparative financial data or prior performance metrics are provided in the filing.

• · The sale includes properties in Sarasota, Florida, and Yountville, California.
• · No financial impact or gain/loss from the sale is disclosed in the filing.
• · No debt paydown or use of proceeds is mentioned.

10-06-2026

On June 5, 2026, an Israeli court approved a debt arrangement for Pacific Oak SOR (BVI) Holdings, Ltd., the indirect wholly owned subsidiary of Pacific Oak Strategic Opportunity REIT, Inc. The arrangement restructures the BVI's Series B and Series D bonds, extending the final maturity to June 30, 2028, and increasing the interest rate from 11.0% to 11.5% after the completion date. While the outstanding principal amounts (NIS 388,237,587 for Series B and NIS 587,063,000 for Series D) are not reduced, the company will receive limited operational funding of up to approximately $2.9 million plus $61,000 per month from the BVI under a second loan, but the BVI faces significant operational restrictions and must maintain a minimum liquidity reserve of $6.0 million.

• · The Debt Arrangement was approved by bondholders before court approval.
• · The BVI's board of directors was reconstituted to include directors supported by bondholders.
• · An administrator was appointed under Israeli insolvency law to decide creditor claims and pursue certain claims on behalf of the BVI, but does not have management authority.
• · The Second Loan does not require the BVI to advance any minimum amount; advances are at the BVI's discretion based on an approved budget and sufficient available funds.
• · The Company and Partnership's sole remedy for BVI breach of the Second Loan is termination; they cannot seek damages.
• · The Company may appoint a director to BVI board meetings subject to bondholder approval.
• · The Company agreed not to initiate insolvency proceedings against the BVI as a condition of the Second Loan.
• · The Second Loan is governed by Israeli law with exclusive jurisdiction in the Tel Aviv–Jaffa District Court.
• · The Company plans to provide an update with related documents on a subsequent Form 8-K upon the Completion Date.

10-06-2026

TransparentBusiness Inc. (formerly Unicoin Inc.) entered into an Asset Swap Agreement on June 10, 2026, to acquire assets located in the Philippines in exchange for unicoins (UNCN) valued as cash-equivalent consideration. The agreement includes a vesting schedule tied to the scheduled public launch of Unicoin on September 28, 2026, with 20% released at launch and 5% monthly thereafter. However, the agreement is subject to significant risks including potential Project Failure, due diligence findings, and regulatory challenges that could nullify the transaction.

• · The agreement involves assets located in the Republic of the Philippines, officially registered as per Exhibit A.
• · Investor represents that it is not a 'U.S. Person' as defined in Regulation S of the Securities Act of 1933.
• · The Company may nullify the agreement without liability for material misrepresentations, due diligence issues, failure to close, or Project Failure.
• · In case of Project Failure, the Company must reconvey the Assets to Investor at its own cost, with Investor bearing applicable taxes and fees.
• · Investor must comply with KYC/AML requirements and is not on any sanctions list.
• · The Unicoin Allocation amount and Assets Value are left blank in the filing, indicating they are negotiated and not disclosed.